Page 40 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat

What you must know about viral hepatitis management in cancer patients

Yi-Hsiang Huang, MD, Ph.D.

Chief, Division of Gastroenterology & Hepatology, Taipei Veterans General Hospital;
Professor, Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

In Taiwan, liver cancer is the second most common cancer in men and the fifth in women. It is also the

third most common cause of cancer mortality. Based on many researches, it is well established that
HBV and HCV infection are highly associated with the occurrence and the progression of
hepatocellular carcinoma (HCC), in Taiwan approximately 60% and 40% of all HCC cases are
associated with HBV and HCV, respectively.

There are many viral factors could increase the risk of HCC, such as high vial loads, high ALT,
advanced fibrosis stage etc. Therefore, HBV and HCV infected patients should be more cautious in
managing with their disease and proactively intervening early to prevent disease progression and to

reduce the risk of HCC. For those HCC patients after curative therapy, they can reduce HCC
recurrence risk and to improve recurrence-free survival through regular oral treatment.